Aghajanian C et al. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gyn Oncol 2021;162(2):375-81. Abstract

Alvarez Secord A et al. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR-alpha) expression. SGO 2022;Abstract 300.

Alqaisi H et al. OZM-114: Phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and/or PALB2 mutation. ASCO 2021;Abstract TPS5621.

Banerjee et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(12):1721-31. Abstract

Banerjee S et al. Phase II study of olaparaib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO 2022;Abstract 529MO.

Bolton KL et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res 2022;[Online ahead of print]. Abstract

Drapkin R et al. Evaluation of NaPi2b expression in a well-annotated longitudinal tissue series of ovarian serous carcinomas. IGCS 2022;Abstract 408.

Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in the germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). ESMO 2019;Abstract 1190PD.

Gonzalez Martin A et al. Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. ASCO 2021;Abstract 5518.

Gu S et al. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci USA 2021;118(25):e202663118. Abstract

Hardesty M et al. Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following frontline platinum-based chemotherapy with bevacizumab. SGO 2022;Abstract 40.

Hays J et al. UPGRADE: Phase 1 combination trial of the NaPi2b-directed antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer. IGCS 2022;Abstract TIP446.

Kasherman L et al. Angiogenesis: A pivotal therapeutic target in the drug development of gynecologic cancers. Cancer Basel 2022;14(5):1122. Abstract

Kasherman L et al. Can TP53 variant negative be high-grade serious ovarian carcinoma? A case series. Gynec Oncol Rep 2021;36:100729. Abstract

Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9. Abstract

Kristeleit R et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BCRA2 mutation (ARIEL4): An international, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(4):465-78. Abstract

Lheureux S. Multi-omics uncovering different faces of clear-cell ovarian cancer. Clin Cancer Res 2022;[Online ahead of print]. Abstract

Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.

Liu J et al. An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial. SGO 2021;Abstract 10415.

Liu S et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systemic review and meta-analysis. Gynecol Oncol 2021;161(2):601-12. Abstract

Liu SL et al. Patterns of first-line systemic therapy delivery and outcomes in advanced epithelial ovarian cancer in Ontario. Curr Oncol 2022;29(8):5988-6009. Abstract

Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. SGO 2022;Abstract LBA 4.

Matulonis UA et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR-alpha) expression: Characterization of antitumor activity in the SORAYA study. ASCO 2022;Abstract 5512.

McMullen M et al. New approaches for targeting platinum-resistant ovarian cancer. Sem Cancer Biol 2021;77:167-81. Abstract

Monk BJ et al. A randomized, phase III trial of evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;[Online ahead of print]. Abstract

Monk BJ et al. ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer 2021;31(12):1589-94. Abstract

Monk BJ et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. ASCO 2022;Abstract LBA5500.

Okamoto A et al. A randomized phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort. SGO 2022;Abstract 329.

O’Malley DM et al. Mirvetuximab soravtansine, a folate receptor alpha (FR-alpha)-targeting antibody drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. ASCO 2021;Abstract 5504.

Oza AM et al. Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and deleterious BRCA1/2 mutation. ESMO 2022;Abstract 518O.

Oza AM et al. Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer. ASCO 2022;Abstract 5579.

Piedimonte S et al. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer. SGO 2022;Abstract 190.

Poveda A et al. Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1/BRCA2 mutation: Final overall survival results from the OPINION trial. ESMO 2022;Abstract 2799.

Poveda A et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol 2022;164(3):498-504. Abstract

Poveda A et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):620-31. Abstract

Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. ESMO 2021;Abstract LBA33.

Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.

Richardson D et al. Updated results from the phase 1 expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 76.

Richardson DL et al. Comparison of AnPi2b expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UpRi; XMT-1536) supports a strategy of testing in archival material. IGCS 2022;Abstract 425.

Richardson DL et al. UPLIFT (ENGOT-ov67/GOG-3048): A pivotal cohort of the XMT-1536-1 trial of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer. IGCS 2022;Abstract TIP428.

Richardson DL et al. UP-NEXT (GOG-3049/ENGOT-ov71-NSGO-CTU): A study of upifitamab rilsodotin (UpRi), a NaPi2b-directed antibody-dug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. IGCS 2022;Abstract TIP453.

Schoutrop E et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol 2022;[Online ahead of print]. Abstract

Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 5558.

Shickh S et al. “Game Changer”: Health professionals’ views on the clinical utility of circulating tumor DNA testing in hereditary cancer syndrome management. Oncologist 2022;27:e393-401. Abstract